Other topics in this section

Hepatitis B: latest news

Hepatitis B resources

  • Hepatitis B

    The majority of people with hepatitis B do not have any symptoms.It is recommended that people living with HIV are tested and vaccinated for hepatitis...

    From: Factsheets

    Information level Level 2
  • Hepatitis B

    Hepatitis B virus (HBV) is an infection that can cause severe liver damage, sometimes resulting in death. Hepatitis B is very common around the world, particularly in Africa, the...

    From: Booklets

    Information level Level 2
  • Hepatitis B treatment

    Treatments are available if your immune system does not naturally clear hepatitis B infection. The aims of hepatitis B treatment include stopping HBV reproduction, reducing liver inflammation and...

    From: Booklets

    Information level Level 2
  • Hepatitis vaccinations

    Effective vaccinations are available to protect against hepatitis A and hepatitis B. There is currently no vaccine against hepatitis C. All people with HIV should have these vaccinations unless...

    From: Booklets

    Information level Level 2
  • HIV & hepatitis

    This booklet gives information for people with HIV who also have hepatitis A, hepatitis B or hepatitis C....

    From: Booklets

    Information level Level 2

Hepatitis B features

Hepatitis B news from aidsmap

More news

Hepatitis B news selected from other sources

  • Graphene sensor could speed hepatitis diagnosis

    Researchers in the UK and China are joining forces to develop a graphene-based sensor for on-the-spot diagnosis of hepatitis A, B and C. Particularly useful in areas with a high incidence of the highly infectious liver disease, such as China, the sensor could help stop the spread of hepatitis by speeding up diagnosis and allowing treatment to start more quickly.

    19 May 2017 | The Engineer
  • EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

    Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection.

    24 April 2017 | EASL
  • New hepatitis data highlight need for urgent global response

    New WHO data reveal that an estimated 325 million people worldwide are living with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. The WHO Global hepatitis report, 2017 indicates that the large majority of these people lack access to life-saving testing and treatment. As a result, millions of people are at risk of a slow progression to chronic liver disease, cancer, and death.

    21 April 2017 | World Health Organization
  • WHO guidelines on hepatitis B and C testing

    These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.

    21 February 2017 | World Health Organization
  • European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection

    Vemlidy® is the First New Treatment for Chronic Hepatitis B Infection to be Approved in the European Union in Nearly a Decade

    12 January 2017 | Gilead press release
  • U.S. Food and Drug Administration Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection

    Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy® (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease.

    11 November 2016 | Gilead press release
  • HCV Drugs May Reactivate HBV, FDA Warns

    Patients with a past or current hepatitis B virus (HBV) infection can experience sometimes fatal HBV reactivation if they take any of nine direct-acting antivirals for hepatitis virus C (HCV) infection, the US Food and Drug Administration (FDA) announced today.

    06 October 2016 | Medscape (free registration required)
  • ContraVir Reports New CRV431 Data Highlighting Synergistic Activity with CMX157 Against Hepatitis B

    ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced that it has taken a major step forward in its pursuit of a potentially curative combination therapy for chronic hepatitis B (HBV).

    12 September 2016 | ContraVir press release
  • Act now for a Hepatitis-free Indonesia

    In the archipelago, hepatitis B is a virus that affects around 28 million people, or roughly around 10 percent of the population, with 14 million people at risk of the virus developing into chronic cirrhosis or liver failure.

    07 September 2016 | Jakarta Post
  • High cost hampers treatment of hepatitis B, C in Vietnam: experts

    A course of treatment for the diseases costs up to VND45 million (US$2,016), according to Nguyen Van Kinh, director of the National Hospital for Tropical Diseases.

    31 August 2016 | Thanh Nien Daily
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.